TRAIL, CAS No.rp175315, death receptor 4;Agonist of death receptor 5

Features and benefits
    Item Number
    rp175315
    Grouped product items
    SKUSizeAvailabilityPrice Qty
    rp175315-500μg
    500μg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $1,334.90
    rp175315-1mg
    1mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $2,334.90

    Basic Description

    Product NameTRAIL, CAS No.rp175315
    SynonymsApo-2 ligand (Apo-2L)
    GradeMoligand™
    Specifications & PurityMoligand™
    Action TypeAGONIST
    Mechanism of actiondeath receptor 4;Agonist of death receptor 5

    Associated Targets(Human)

    TNFRSF10A Tchem Tumor necrosis factor receptor superfamily member 10A (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
    TNFRSF10B Tbio Tumor necrosis factor receptor superfamily member 10B (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

    Product Specifications

    CASrp175315

    Certificates

    Certificate of Analysis(COA)

    Enter Lot Number to search for COA:

    Genetic information

    Alternate NamesApo-2 ligand (Apo-2L)
    Reference
    • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
    • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
    • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
    • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
    • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
    • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
    • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
    • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
    • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
    • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more

    Related Documents

    References

    1. Cao L, Du P, Jiang SH, Jin GH, Huang QL, Hua ZC.  (2008)  Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature..  Mol Cancer Ther,  (4): (851-61).  [PMID:18413798]
    2. Huang K, Duan N, Zhang C, Mo R, Hua Z.  (2017)  Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle..  Sci Rep,  (3): (41904).  [PMID:28225020]

    Solution Calculators